Biogen

BIIB

Market cap $21B

Overview Fund Activity

143.32 USD

-1.54

1.06%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

143.36

+0.04

0.03%

1 day

-1.06%

5 days

1.53%

1 month

3.41%

3 months

9.37%

6 months

-0.15%

Year to date

-4.45%

1 year

-28.19%

5 years

-48.53%

10 years

-55.19%

About: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Employees: 7,605

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

150% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 5 (+3) [Q2]

30% more repeat investments, than reductions

Existing positions increased: 337 | Existing positions reduced: 260

14% more call options, than puts

Call options by funds: $381M | Put options by funds: $333M

1.4% more ownership

Funds ownership: 86.75% [Q1] → 88.15% (+1.4%) [Q2]

4% less first-time investments, than exits

New positions opened: 94 | Existing positions closed: 98

2% less funds holding

Funds holding: 867 [Q1] → 850 (-17) [Q2]

7% less capital invested

Capital invested by funds: $17.4B [Q1] → $16.2B (-$1.14B) [Q2]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$118

18% downside

Avg. target

$162

13% upside

High target

$219

53% upside

5 analyst ratings

2 positive

40%

3 neutral

60%

0 negative

0%

Piper Sandler David Amsellem	$118	Neutral Maintained	14 Aug 2025
Citigroup Geoff Meacham	$135	Neutral Maintained	1 Aug 2025
RBC Capital Brian Abrahams	$219	Outperform Maintained	1 Aug 2025
Morgan Stanley Matthew Harrison	$144	Equal-Weight Maintained	1 Aug 2025
HC Wainwright & Co. Andrew Fein	$194	Buy Maintained	1 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 14 articles about BIIB published over the past 30 days

Biogen Inc. (BIIB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Biogen Inc. (NASDAQ:BIIB ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 10:45 AM EDT Company Participants Christopher Viehbacher - President, CEO & Director Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Good morning, everybody.

Biogen Inc. (BIIB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Global drugmakers rush to boost US presence as tariff threat looms

Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.

Global drugmakers rush to boost US presence as tariff threat looms

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive, relentless disease LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive, relentless disease

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies –

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB), today announced data from Phase 1/2a and open-label extension (OLE) studies of zorevunersen that support the potential for zorevunersen to be the first disease-modifying medicine for Dravet syndrome. Findings were presented at the 36th International Epil.

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

These Stocks Are Moving the Most Today: Nvidia, Biogen, NIO, Spirit Aviation, and More

Dow Set to Open Down as Markets Reopen After Labor Day S&P 500 and Nasdaq futures are also falling in premarket trading.

These Stocks Are Moving the Most Today: Nvidia, Biogen, NIO, Spirit Aviation, and More

Zacks Investment Research

Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi

BIIB wins FDA approval for Leqembi Iqlik, a fast, subcutaneous option for early Alzheimer's patients transitioning from IV infusions.

Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi

US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug

The U.S. Food and Drug Administration has approved an injectable version of Eisai and Biogen's Alzheimer's disease drug Leqembi, the companies said on Friday, allowing for an easier treatment option following an initial intravenous infusion.

US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug

Investors Business Daily

FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment

Biogen and Eisai won Food and Drug Administration approval of an at-home shot version of their Alzheimer's treatment Leqembi.

FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial treatment of 18 months

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

See News Rankings

Charts implemented using Lightweight Charts™